Novartis is exemplifying strength in the stock market, despite impacts from generics on its blockbuster heart drug. Causing a stir, the company acquired Avidity Biosciences, leading to a downgrade for Avidity's stock by Chardan Capital, but simultaneously instigating a surge for competitor Dyne Therapeutics. Full-year guidance for Novartis has been increased, reflecting this strategic acquisition and overall portfolio growth. The company's CEO defends the $12 billion acquisitions as an 'appropriate risk', a stance supported by some market analysts. Concurrently, the pharma giant reached licensing deals with Arrowhead Pharmaceuticals and Monte Rosa. Despite some stock price fluctuation, Novartis’ future outlook remains optimistic with strong shareholder returns and potential for growth after hitting a new share price high in 2025. This optimism is bolstered by Novartis' solid earnings and a strong branded drug portfolio which supports steady long-term growth. However, Goldman Sachs issued a ‘Sell’ for Novartis stock on growth concerns.
Novartis Stocks News Analytics from Mon, 09 Jun 2025 07:00:00 GMT to Sat, 08 Nov 2025 02:44:08 GMT -
Rating 6
- Innovation 2
- Information 9
- Rumor -5
